Analysis of clinicopathological factors associated with bone metastasis in breast cancer

Abstract

Breast cancer is the second leading cause of cancer death in women today. Once breast cancer metastasizes to bone, mortality increases. Thus, there is an urgent need to identify patients with high risk of bone metastasis, and to find predictive factors for the occurrence of bone metastasis at an earlier stage of breast cancer. Three hundred and sixty patients with pathologically proved breast cancer visiting the Department of Nuclear Medicine for whole body bone scan from January 2006 and January 2009 were investigated in this study. Clinicopathological information was obtained, which consisted of age, menopausal status, clinical staging, lymph node stage, histological grade, the expression of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2). Correlation between bone metastasis and the associated factors was tested by using the Chi-square test. A Cox multivariate analysis was used to assess the factors which independently contributed to survival after bone metastasis in breast cancer patients. Survival curves were drawn for metastasis-free interval and the independent factors which contributed to survival, using the Kaplan-Meier method. Twenty-four patients were excluded from subsequent analysis. Three hundred and thirty-six enrolled patients ranged in age from 22 to 77 years (mean, 47.8 years). ER/PR status [ER(+) vs. ER(−), χ²=4.328, P=0.037; ER(+)PR(+) vs. ER(+)PR(−), χ²=4.425, P=0.035] and histological grade (χ²=7.131, P=0.028) were significantly associated with bone metastasis. ER status (x²=8.315, P=0.004) and metastasis-free interval (χ²=6.863, P=0.009) were independent prognostic factors for survival in breast cancer patients with bone metastasis. Our study suggested that ER/PR status and histological grade are risk factors for the development of bone metastasis in breast cancer patients. However, ER status and metastasis-free interval are independent prognostic factors for survival in breast cancer patients with bone metastasis. Breast cancer bone metastasis has its unique characteristics, which is helpful to choose the appropriate treatment for breast cancer patients with bone metastasis.

Keywords

breast cancer / bone metastasis / bone scan / risk factors

References

[1] PretzD.J., PowlesT.J., MilanJ., et al.. Detection of breast carcinoma metastases in bone: relative merit of X-rays and skeletal scintigraphy. Lancet, 1983, 2(8350): 613-616

[2] ColemanR.E., RubensR.D., FogelmanI.. Reappraisal of the baseline bone scan in breast cancer. J Nucl Med, 1988, 29(6): 1045-1049

[3] Rodriguez-PinillaS.M., SarrioD., HonradoE., et al.. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinoma. Clin Cancer Res, 2006, 12(5): 1533-1539

[4] KoizumiM., YamadaY., TakiguchiT., et al.. Bone metabolic markers in bone metastasis. J Cancer Res Clin Oncol, 1995, 121(9–10): 542-548

[5] CoxD.R.. Regression models and life-tables. J R Stat Soc, 1972, 34: 187-220

[6] SobinL.H., WittekindCh.. SobinL.H., WittekindC.. . TNM Classification of Malignant Tumors, 20026th edGeneva, Wiley-Liss, 131-141

[7] ElstonC.W., EllisI.O.. Pathological prognostic factors in breast cancer: experience from a large study with long term follow-up. Histopathology, 1991, 19: 403-410

[8] MartinT.J., MoseleyJ.M.. Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer, 2000, 7(4): 271-284

[9] JanicekM.J., HayesD.F., KaplanW.D.. Healing flare in skeletal metastases from breast cancer. Radiology, 1994, 192: 201-204

[10] BaumM.. The changing face of breast cancer-past, present and future perspectives. Breast Cancer Res Treat, 2002, 75(Suppl1): s1-s5

[11] JamesJ.J., EvansA.J., PinderS.E., et al.. Bone metastases from breast carcinoma: histopathological radiological correlations and prognostic features. Br J Cancer, 2003, 89(4): 660-665

[12] WilliamsM.R., ToddJ.H., EllisI.O., et al.. Oestrogen receptors in primary and advanced breast cancer: an eight year review of 704 cases. Br J Cancer, 1987, 55(1): 67-73

[13] ArpinoG., WeissH., LeeA.V., et al.. Estrogen receptor-positive, progesterone-receptor negative breast cancer: association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst, 2005, 97(17): 1254-1261

[14] LoiS., Haibe-KainsB., DesmedtC., et al.. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol, 2007, 25(10): 1239-1246

[15] ColemanR.E., SmithP., RubensR.D.. Clinical course and prognostic factors following bone recurrence from breast cancer. Br J Cancer, 1998, 77(2): 336-340

[16] CallahanR., HurvitzS.. Human epidermal growth factor receptor-2-positive breast cancer: current management of early, advanced, and recurrent disease. Curr Opin Obstet Gynecol, 2011, 23(1): 37-43